CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−2.38%Aug 14, 2026, 20:30 UTC
Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.
Source:Aug 12, 2026, 12:00 UTC
Citius Oncology appointed Jonathan Peri as an independent director to its board.
Source: